Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Toronto

$220,000.00

Phase-specific evaluation of cost-effectiveness for lung transplant and ex-vivo lung perfusion

FY 2020-21

Summary
Surgical lung transplantation is the only definitive treatment for lung disease that is unresponsive to medical therapy. In Canada, annual rates of lung transplant and wait-list enrollment continue to increase. However, most donated lungs are determined to be of inadequate quality for safe transplant. Demand for lung transplant now exceeds organ availability, and this may explain the high risk of death among wait-listed patients. Ex-vivo lung perfusion (EVLP) is a promising new technology which allows for rehabilitation of potential donor lungs prior to transplant in a recipient. By rehabilitating injured donor lungs rather than discarding, EVLP may correct the imbalance between supply and demand for lung transplant. However, this technology comes at significant cost to the healthcare system. Few studies have investigated the cost-effectiveness of lung transplant programs or EVLP, and none has done so in the Canadian context. The impact that EVLP may have on the costs and clinical outcomes are yet unclear. We propose to study cost-effectiveness of lung transplant and EVLP. Specifically, we propose to compare outcomes and resource use between patients referred for lung transplant with versus without EVLP, and measure the cost for each phase of transplant care among these patients.
Program
CIHR Fellowship
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
441151
Name
Peel John K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Health Research Training B - HP
Projecttitle
Phase-specific evaluation of cost-effectiveness for lung transplant and ex-vivo lung perfusion
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$220,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Ex-Vivo Lung Perfusion; Health Services Research; Health Technology Assessment; Lung Transplant
Abstract
Surgical lung transplantation is the only definitive treatment for lung disease that is unresponsive to medical therapy. In Canada, annual rates of lung transplant and wait-list enrollment continue to increase. However, most donated lungs are determined to be of inadequate quality for safe transplant. Demand for lung transplant now exceeds organ availability, and this may explain the high risk of death among wait-listed patients. Ex-vivo lung perfusion (EVLP) is a promising new technology which allows for rehabilitation of potential donor lungs prior to transplant in a recipient. By rehabilitating injured donor lungs rather than discarding, EVLP may correct the imbalance between supply and demand for lung transplant. However, this technology comes at significant cost to the healthcare system. Few studies have investigated the cost-effectiveness of lung transplant programs or EVLP, and none has done so in the Canadian context. The impact that EVLP may have on the costs and clinical outcomes are yet unclear. We propose to study cost-effectiveness of lung transplant and EVLP. Specifically, we propose to compare outcomes and resource use between patients referred for lung transplant with versus without EVLP, and measure the cost for each phase of transplant care among these patients.
Competitiondate
202012
Approvedterm2
4 yrs 0 mth
Pinamesdelim
Peel, John K
Approvedterm
4 ans 0 mois
Cihrcontribution2
~ $220,000~ $0~
University of Toronto - $220,000 Grant (2020-21) | Canada Spends